Could a common drug alter muscle relaxants in surgery?
NCT ID NCT05716256
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial investigates whether ulinastatin, a drug sometimes used during surgery, affects the action of two common muscle relaxants (rocuronium and cisatracurium). The study involves 120 adults aged 25 to 60 undergoing pancreatic surgery. Researchers measure how quickly the muscle relaxants take effect and how long they last, comparing those who receive ulinastatin to those who get a placebo. The goal is to improve anesthesia care by understanding potential drug interactions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ulinastatin
- What this could lead to
- If ulinastatin changes how muscle relaxants work, it could help anesthesiologists adjust doses for safer surgeries.
- What could go wrong
- This is a small, early-stage study in one type of surgery. Results may not apply to other patients or procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
120 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Jun 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients undergo elective pancreaticoduodenectomy surgery 2. Age ranging from 25 to 60 years，body mass index (BMI)18-24kg/m2, American Society of Anesthesiologists (ASA) grades 1 or 2. 3. Receive general anesthesia and muscle relaxants intraoperatively. Exclusion Criteria: 1. patients ASA class 3 and above 2. Severe cardiac or respiratory diseases, liver( Child-Pugh class B or C ) or kidney disease( estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m²) 3. Pregnant women. 4. Patients with neurological dysfunction including myasthenia gravis, epilepsy or psychiatric disorders 5. Patients on any premedications including antisialagogues . 6. Patients on drugs known to interfere with neuromuscular transmission including but not exclusive to anticonvulsants, calcium channel blockers, β-blockers, corticosteroids, diuretics and antibiotics of the aminoglycoside group 7. Patients known allergy to propofol and sufentanil or remifentanil, 8. emergency operations. 9. Patients judged by the investigator to be unsuitable for participation in this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nondepolarising muscle relaxants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China